Blog

InSphero CEO Jan Lichtenberg muses about how far 3D cell-based technology has come since InSphero was founded in 2009 and shares the latest news about

Model systems, whether laboratory animals or human cell-based systems, have long been central to the discovery and development of new and better drugs for the

InSphero Senior Application Scientist Sue Grepper explains why critical limitations of dietary and genetically modified rodent models for NASH may be slowing down drug discovery

InSphero CEO Jan Lichtenberg and renowned liver disease expert Dr. Scott Friedman of the Icahn School of Medicine at Mount Sinai recently talked to PharmaExec

InSphero's Akura™ technology platforms team worked with Professor Andreas Hierlemann's Bioengineering Laboratory at ETH Zürich to develop a microfluidic hanging drop system for embryotoxicity testing.

InSphero CEO Jan Lichtenberg reflects on ADA2019 and how InSphero is enabling T1D and T2D Discovery with our 3D InSight™ Diabetes Discovery Platform. Over the

Microfluidic chips enable researchers to manipulate, image, and analyze small tissue constructs under optimal culturing conditions. Microfluidics, the technology behind emerging body-on-a-chip and organs-on-chips systems,

Pharma companies racing to accelerate drug discovery for chronic liver diseases, such as NASH and fibrosis, need better preclinical testing tools for compound screening and

Correlating human pancreas donor characteristics with 3D InSight™ Islet Microtissue functionality confirms reaggregated islets are a robust, physiologically relevant model for diabetes research. With diabetes

InSphero and Agilent discuss the need for metabolically competent models with stable metabolic activity for mitochondrial toxicity testing in a new textbook chapter. Mitochondrial Dysfunction